Brain seizures may originate from an unexpected metabolic cascade involving the amino acid D-serine, offering new therapeutic targets for the 65 million people worldwide living with epilepsy. This mechanistic discovery could shift treatment approaches from symptom suppression to addressing root cellular causes. The research identifies a three-way connection between compromised mitochondrial function, inflammatory brain responses, and abnormal D-serine signaling that culminates in seizure activity. When cellular powerhouses fail to maintain energy balance, they trigger inflammatory cascades that dysregulate D-serine production—an amino acid critical for normal brain communication through NMDA receptors. This disrupted signaling creates conditions where neurons become hyperexcitable and prone to the synchronized firing patterns characteristic of seizures. The pathway represents a departure from traditional epilepsy models that focus primarily on ion channel dysfunction or neurotransmitter imbalances. Understanding this mitochondrial-inflammatory-metabolic axis opens possibilities for combination therapies targeting multiple points in the cascade rather than just downstream seizure symptoms. The findings align with growing recognition that epilepsy involves complex metabolic dysfunction, not merely electrical abnormalities. For treatment-resistant epilepsy—affecting roughly one-third of patients—interventions addressing mitochondrial health or D-serine metabolism could prove more effective than conventional anticonvulsants. However, the research appears to be mechanistic rather than clinical, meaning practical applications remain years away. The complexity of simultaneously modulating mitochondrial function, neuroinflammation, and amino acid metabolism presents significant pharmaceutical challenges, though the pathway's specificity could enable more targeted interventions with fewer systemic side effects.